FluoGuide is trading at SEK 35.10, down 6.9% today, as the stock faces pressure from profit-taking and a broader decline in the biotechnology sector.
- The sharp drop lacks any fresh, company-specific news catalysts, with no new trial results, earnings, or guidance changes reported.
- The move appears driven by a risk-off sentiment across the industry, with the broader biotech sector ETF (XBI) trading down approximately 2.45%.
- Investors continue to monitor the company's progress following earlier financing rounds intended to fund its Phase II clinical trials.